Summary
3-Deazaguanine (Dezaguanine), a purine antimetabolite, was evaluated in a phase I trial in 42 patients with advanced solid tumors. Dezaguanine was given as a weekly intravenous infusion for three consecutive weeks of a four-week cycle. The dose ranged from 30 to 2000 mg/m2; no consistent dose-limiting hematologic or gastrointestinal toxicity was observed. Some patients reported brief episodes of burning at the infusion site or transient facial flushing immediately following the administration of dezaguanine. Three patients experienced cardiac toxicity. Two patients, at doses of 1130 and 2000 mg/m2 respectively, developed congestive heart failure. In one case the heart failure was fatal; the second patient recovered within 8 weeks. The third patient had a progressive fall in left ventricular ejection fraction but did not develop clinical evidence of heart failure before his death from progressive cancer two months later. Postmortem cardiac pathology in the two patients who died early following therapy revealed nonspecific interstitial fibrosis without inflammatory cell infiltrates. The myocardium of the third patient, who died 20 months after receiving dezaguanine, was normal. Electron microscopic analysis of myocardium from the first patient did not show myofibrillar loss or mitochondrial disorganization characteristic of anthracycline cardiomyopathy. Due to the probable cardiotoxicity of dezaguanine in this study and the lack of objective antitumor response, further development of this agent has been discontinued.
Similar content being viewed by others
References
Corbett TH, Griswold DP, Roberts BJ, Peckham JC, Schabel FM, Jr.: Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat Rep 62:1471–1488, 1978
DeLap R: CI-908 (Dezaguanine) investigator's brochure. Warner Lambert/Parke-Davis Research Report, No. RR 720-00994, 1983
Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Rubens RD: A project of the programme in clinical oncology of the international union against cancer, Geneva, Switzerland. Cancer 39:1289–1294, 1977
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981
Von Hoff DD, Rozencweig M, Piccart M: The cardiotoxicity of anticancer agents. Semin Oncol 9:23–33, 1982
Unverferth DV, Unverferth BJ, Balcerzak SP, Bashore TA, Neidhart JA: Cardiac evaluation of mitoxantrone. Cancer Treat Rep 67:343–350, 1983
Hall TC, Krant MJ, Lloyd JB: Treatment of localized inoperable neoplasms with intra-arterial infusions of 8-azaguanine. Cancer 15:1156–1164, 1962
Haq MM, Legha SS, Choksi J: Doxorubicin-induced congestive heart failure in adults. Cancer 56:1361–1365, 1985
Bristow MR, Mason JW, Billingham ME, Daniels JR: Doxorubicin cardiomyopathy: Evaluation by phenocardiography, endomyocardial biopsy and cardiac catheterization. Ann Int Med 88:168–175, 1978
Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC: Early anthracycline cardiotoxicity. Am J Med 65:823–832, 1978
Author information
Authors and Affiliations
Additional information
This study was previously reported in part (Proc. Amer. Soc. Clin. Oncol. 6: 47 (1987), abstract #180).
Rights and permissions
About this article
Cite this article
Margolin, K., Doroshow, J., Leong, L. et al. 3-Deazaguanine: Report of a phase I trial and drug-related cardiac toxicity. Invest New Drugs 8, 369–376 (1990). https://doi.org/10.1007/BF00198593
Issue Date:
DOI: https://doi.org/10.1007/BF00198593